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The last decade has witnessed a huge expansion in the field of Tumour I mmunology. A large 
number of tumour antigens recognized by T lymphocytes have been identified and new 
techniques have enabled the direct ex vivo analysis of epitope-specific cytotoxic T lymphocytes 
(CTL). These developments provide the tools with which spontaneous tumour antigen-specific 
CTL responses can be characterized in detail, have facilitated the development of antigen-specific 
tumour immunotherapeutic strategies, and have heralded a new era of immunomonitoring in 
clinical trials. In this work, ex vivo phenotypic and functional analyses of CTL specific for an 
HLA-A*0201-restricted epitope encoded by the mel an-A tumour differentiation antigen (mel an­
A26-35) were performed on samples from melanoma patients and normal healthy donors. Ex vivo 
tetramer analysis revealed circulating melan-A26_35-specific T lymphocytes in 50% of both 
patients and normal donors. Phenotypic analysis of tetramer+ cells was correlated with ex vivo 
assays of CTL function. In the normal donors and approximately 50% of patients, the melan-A26 _ 
35-specific cells were always phenotypically and functionally naIve. However, in the remaining 
patients, a proportion of melan-A26_35-specific cells were phenotypically antigen-experienced, and 
functional responses to peptide could readily be detected ex vivo. The observation in patients, that 
tumour antigen-specific CTL responses with effector function are "too little, too late", provided 
the basis for a clinical trial of recombinant plasmid DNA and Modified Vaccinia Ankara in 
patients with surgically-treated melanoma and a high risk of disease recurrence. Both vaccines 
were engineered to encode the same polyepitope string of seven HLA-A2- and HLA-Al­
restricted tumour antigen epitopes, including the high affinity melan-A26-35 analogue. 
Immunomonitoring, which included detailed kinetic analyses of tetramer+ cells, demonstrated 
that MV A was capable of generating an expansion of melan-A26_35-specific CTL w ith effector 
function in approximately 50% of patients. However, no responses to the other tumour antigen 
epitopes were seen. A detailed analysis of CTL responses specific for recently-identified 
vaccinia-encoded epitopes (including a new epitope identified as part of this work) demonstrated 
that CTL responses specific for the viral vector were dominant over those for the recombinant 
epitopes. This finding has important implications for the future design of recombinant viral 
vaccmes. 
